=> file caplus
FILE 'CAPLUS' ENTERED AT 15:51:04 ON 18 MAY 2005

FILE COVERS 1907 - 18 May 2005 VOL 142 ISS 21
FILE LAST UPDATED: 17 May 2005 (20050517/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 12 SEA FILE=REGISTRY SSS FUL L1
L4 6 SEA FILE=CAPLUS L3

=> d l4 1-6 ibib abs hitstr

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:636024 CAPLUS
DOCUMENT NUMBER: 135:210825
TITLE: Preparation of 1-phenoxy-3-amino-2-propanols as β3 adrenergic receptor agonists
INVENTOR(S): Taniguchi, Kiyoshi; Kayakiri, Hiroshi; Sakurai, Minoru; Fujii, Naoaki; Washizuka, Kenichi; Hamashima, Hitoshi; Tomishima, Yasuyo; Hamada, Kaori; Yamamoto, Nobuhiro; Ishikawa, Hirofumi; Unami, Naoko; Miura, Toshiko

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062705	A2	20010830	WO 2001-JP1442	20010226
WO 2001062705	A3	20030116		
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1292564	A2	20030319	EP 2001-906332	20010226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2003525882	T2	20030902	JP 2001-561715	20010226
US 2003073846	A1	20030417	US 2002-181970	20020806
PRIORITY APPLN. INFO.:			AU 2000-5850 A	20000228
			WO 2001-JP1442 W	20010226

OTHER SOURCE(S): MARPAT 135:210825
GI



I



II

AB The title compds. (I) [wherein X1 = a bond or O(CH2)m; m = 1-3; X2 = a bond, (CH2)n, or CH2O; n = 1-3; R1 = H or amino protective group; R2 = hydroxyalkyl or alkoxyalkyl; A = (un)substituted Ph, pyridyl, indolyl, or carbazolyl; B = (un)substituted Ph or pyridyl; or pharmaceutically acceptable salts thereof] were prepared as β3 adrenergic receptor agonists. For example, refluxing (S)-(oxiranylmethoxy)benzene, (S)-3-(4-hydroxyphenyl)-1-propanol•HCl, and N,N-diisopropylethylamine in MeOH afforded II. The latter in dogs reduced carbachol-induced increase in intravesical pressure from 6.8 mm Hg (controls) to 2.0 mm Hg. I are useful for the prophylactic and/or therapeutic treatment of pollakiuria, urinary incontinence, a wasting condition, or emaciation.

IT **204592-94-9P 357409-00-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenoxyaminopropanols as β3 adrenergic receptor agonists for treatment of pollakiuria, urinary incontinence, wasting conditions, or emaciation)

RN 204592-94-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 357409-00-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:380578 CAPLUS
DOCUMENT NUMBER: 135:5531
TITLE: Process for the preparation of aryloxypropanolamines from oxiranylmethoxyarenes and pyridinyloxyphenylbutylamines.
INVENTOR(S): Hopkins, Randall Bruce; Hancock, Deana Lori; Quimby, Michael Eugene; Rothhaar, Roger Ryan; Werner, John Arnold; Bush, Julie Kay; Dunlap, Steven Eugene; Fisher, Jack Wayne
PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036412	A1	20010525	WO 2000-US30128	20001113

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165594P P 19991115
OTHER SOURCE(S): MARPAT 135:5531
GI



I



II



III

AB Title compds. [I; R1 = (substituted) aryl; R2 = alkyl, (substituted) aralkyl], were prepared by reaction of oxiranylmethoxyarenes (II; R1 = specified aryl) with amines (III; R2 as above) followed by reaction with an acid to form a quaternary ammonium salt, and optional crystallization Thus, 4-[(2S)-oxiranylmethoxy]-1H-indole and Me 2-[4-(2-amino-2-methylpropyl)phenoxy]-3-pyridine were heated in MeOH at 70° for 24 h to give 89% Me (S)-2-[4-[2-[2-hydroxy-3-(1H-indol-4-yloxy)propylamino]-2-methylpropyl]phenoxy]-3-pyridinecarboxylate (IV) of 86.5% purity. The 2-hydroxyacetate salt of IV was prepared in 84% yield and 97.5% purity.

IT **204592-94-9P 341510-20-1P 341510-21-2P 341510-23-4P 341547-59-9P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for the preparation of aryloxypropanolamines from oxiranylmethoxyarenes and pyridinyloxyphenylbutylamines)

RN 204592-94-9 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 341510-20-1 CAPLUS
CN Acetic acid, hydroxy-, compd. with 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 79-14-1
CMF C2 H4 O3



RN 341510-21-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, monobenzoate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 65-85-0
CMF C7 H6 O2



RN 341510-23-4 CAPLUS
CN Benzoic acid, 4-hydroxy-, compd. with 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 99-96-7
CMF C7 H6 O3



RN 341547-59-9 CAPLUS
CN Benzoic acid, 4-methyl-, compd. with 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-3-pyridinecarboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 99-94-5

CMF C8 H8 O2



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:155240 CAPLUS
DOCUMENT NUMBER: 135:40399
TITLE: β3-Adrenergic receptor ligands: insight into structure-activity relationships using Monte-Carlo conformational analysis in water
AUTHOR(S): De Amici, M.; De Micheli, C.; Kassi, L.; Carrea, G.; Ottolina, G.; Colombo, G.
CORPORATE SOURCE: Istituto di Chimica Farmaceutica e Tossicologica, Universita di Milano, Milan, 20131, Italy
SOURCE: Tetrahedron (2001), 57(9), 1849-1855
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB This paper deals with the application of a Monte-Carlo (MC)-based conformational anal. carried out in water on a set of known β3-adrenergic ligands. On the basis of their conformation at the global min., the mols. under study can be grouped into two clusters: the 'extended' and the 'folded' cluster. Each cluster is identified by well-defined values of torsion angles and distances between the pharmacophoric groups. It is worth noting that a ligand included in the cluster characterized by an extended conformation invariably shows a higher affinity for the human β3-adrenoreceptor with respect to the corresponding rodent receptor.

IT **204592-94-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(structure-activity relationships of β3-adrenergic receptor agonists and antagonists using Monte-Carlo conformational anal. in water)

RN 204592-94-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:78218 CAPLUS
DOCUMENT NUMBER: 134:125969
TITLE: Method using aryloxypropanolamine β3 adrenergic agonists for treating type II diabetes and obesity as well as cardiac abnormalities
INVENTOR(S): Bloomquist, William Elmer; Cohen, Marlene Lois
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007026	A2	20010201	WO 2000-US16325	20000712
WO 2001007026	A3	20020228		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-145149P P 19990722
OTHER SOURCE(S): MARPAT 134:125969
GI



I

AB A method is disclosed for agonizing the β3 receptor in a subject in need thereof. The method comprises administering to the subject between about 1.0 to about 5.0 mg/kg body weight/day of an aryloxypropanolamine compound (Markush included). Preferably, between about 2.0 to about 5.0 mg, more preferably 2.0 to about 4.8 mg, and even more preferably between about 3.0 to about 4.8 mg/kg body weight/day are administered. Compds. of the invention include e.g. I.

IT **204592-94-9 204592-97-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aryloxypropanolamine β3 adrenergic agonists for treating type II diabetes and obesity as well as cardiac abnormalities)

RN 204592-94-9 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204592-97-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:78217 CAPLUS
DOCUMENT NUMBER: 134:125949
TITLE: Treatment of cardiac abnormalities with aryloxy propanolamines
INVENTOR(S): Bloomquist, William Elmer; Cohen, Marlene Lois
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007025	A2	20010201	WO 2000-US16320	20000711
WO 2001007025	A3	20020117		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-145174P P 19990722
OTHER SOURCE(S): MARPAT 134:125949

AB Disclosed is a method of treating cardiac dysfunction and cardiac abnormalities with aryloxy propanolamines in a subject in need of such treatment. The EC50 values and KB values of 15 aryloxy propanolamines for tachycardia was determined in rats.

IT **204592-97-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of cardiac abnormalities with aryloxy propanolamines)

RN 204592-97-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:169451 CAPLUS
DOCUMENT NUMBER: 128:230241
TITLE: Preparation of carbazole derivs. as selective β3 adrenergic agonists
INVENTOR(S): Crowell, Thomas A.; Evrard, Deborah A.; Jones, Charles D.; Muehl, Brian S.; Rito, Christopher J.; Shuker, Anthony J.; Thorpe, Andrew J.; Thrasher, Kenneth J.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Crowell, Thomas A.; Evrard, Deborah A.; Jones, Charles D.; Muehl, Brian S.; Rito, Christopher J.; Shuker, Anthony J.; Thorpe, Andrew J.; Thrasher, Kenneth J.
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9809625	A1	19980312	WO 1997-US15230	19970828
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 827746	A1	19980311	EP 1997-306613	19970827
EP 827746	B1	20020403		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 215369	E	20020415	AT 1997-306613	19970827

ES 2171839	T3	20020916	ES 1997-306613		19970827
CA 2236269	AA	19980312	CA 1997-2236269		19970828
AU 9740941	A1	19980326	AU 1997-40941		19970828
JP 2002513387	T2	20020508	JP 1998-512756		19970828
ZA 9707917	A	19990603	ZA 1997-7917		19970903
US 6140352	A	20001031	US 1998-68192		19980504
US 6413991	B1	20020702	US 2000-610096		20000630
US 2002165234	A1	20021107	US 2002-120302		20020410
US 6686372	B2	20040203			
US 2005043337	A1	20050224	US 2003-694467		20031027
PRIORITY APPLN. INFO.:			US 1996-25818P	P	19960905
			US 1996-29228P	P	19961030
			WO 1997-US15230	W	19970828
			US 1998-68192	A3	19980504
			US 2000-610096	A1	20000630
			US 2002-120302	A1	20020410

OTHER SOURCE(S): MARPAT 128:230241

GI



II

AB Title compds. R1X1CH(OH)CH2N(R3)C(R5R6)X2X3R4 I (X1 = OCH2, SCH2, bond; X2 = bond, alkylene; X3 = O, S, bond; R1 = fused heterocycle; R3 = H, alkyl; R4 = (un)substituted heterocycle, naphthyl, etc.; R5 = H, alkyl; R6 = H, alkyl CO-O-alkyl; R5-R6 = cycloalkyl; R6-X2 = cycloalkyl; etc.) are prepared for selective β3 receptor agonists which are useful in the treatment of Type II diabetes and obesity, comprising administering to mammal. The title compound II was prepared from (2S)-(+)-4-(oxiranylmethoxy)-9H-carbazole and 2-(4-(2-amino-2-methylpropyl)phenoxy)-5-pyridinecarbonitrile which was prepared from 2-fluoropyridine and 4-(2-amino-2-methylpropyl)phenol.

IT **204592-90-5P 204592-94-9P 204592-97-2P**
204593-31-7P 204593-32-8P 204593-36-2P
204593-37-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carbazole derivs. as adrenergic agonists)

RN 204592-90-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]propyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204592-94-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204592-97-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 204593-31-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-[(1-fluoro-9H-carbazol-4-yl)oxy]-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204593-32-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-[(8-fluoro-9H-carbazol-4-yl)oxy]-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204593-36-2 CAPLUS
CN Butanedioic acid, compd. with (S)-6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-3-pyridinecarboxamide (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 204593-37-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatall
FILE 'USPATFULL' ENTERED AT 15:51:50 ON 18 MAY 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:51:50 ON 18 MAY 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 12 SEA FILE=REGISTRY SSS FUL L1
L5 6 SEA L3

=> d l5 1-6 ibib abs hitstr

L5 ANSWER 1 OF 6 USPATFULL on STN

ACCESSION NUMBER:	2005:50537 USPATFULL
TITLE:	Selective beta3 adrenergic agonists
INVENTOR(S):	Rito, Christopher J., Mooresville, IN, UNITED STATES Shuker, Anthony J., Indianapolls, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005043337	A1	20050224
APPLICATION INFO.:	US 2003-694467	A1	20031027 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-120302, filed on 10 Apr 2002, GRANTED, Pat. No. US 6686372 Continuation of Ser. No. US 2000-610096, filed on 30 Jun 2000, GRANTED, Pat. No. US 6413991 Division of Ser. No. US 1998-68192, filed on 4 May 1998, GRANTED, Pat. No. US 6140352 A 371 of International Ser. No. WO 1997-US15230, filed on 28 Aug 1997, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-25818P	19960905 (60)
	US 1996-29228P	19961030 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288
NUMBER OF CLAIMS:	52
EXEMPLARY CLAIM:	1
LINE COUNT:	3221

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β.sub.3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating Type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of

formula (I). ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **204592-90-5P 204592-94-9P 204592-97-2P**
204593-31-7P 204593-32-8P 204593-36-2P
204593-37-3P
(preparation of carbazole derivs. as adrenergic agonists)

RN 204592-90-5 USPATFULL

CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]propyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204592-94-9 USPATFULL

CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204592-97-2 USPATFULL

CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 204593-31-7 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-[(1-fluoro-9H-carbazol-4-yl)oxy]-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204593-32-8 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-[(8-fluoro-9H-carbazol-4-yl)oxy]-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204593-36-2 USPATFULL
CN Butanedioic acid, compd. with (S)-6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-3-pyridinecarboxamide (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 204593-37-3 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



L5 ANSWER 2 OF 6 USPATFULL on STN

ACCESSION NUMBER:	2003:106933 USPATFULL
TITLE:	Aminoalcohol derivatives
INVENTOR(S):	Taniguchi, Kiyoshi, Osaka, JAPAN Kayakiri, Hiroshi, Osaka-shi, JAPAN Sakurai, Minoru, Osaka-shi, JAPAN Fujii, Naokaki, San Francisco, CANADA Washizuka, Kenichi, Osaka-shi, JAPAN Hamashima, Hitoshi, Osaka-shi, JAPAN Tomishima, Yasuyo, Osaka-shi, JAPAN Hamada, Kaori, Osaka-shi, JAPAN Yamamoto, Nobuhiro, Osaka-shi, JAPAN Ishikawa, Hirofumi, Osaka-shi, JAPAN Unami, Naoko, Osaka-shi, JAPAN Miura, Toshiko, Osaka-shi, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003073846	A1	20030417	
APPLICATION INFO.:	US 2002-181970	A1	20020806	(10)
	WO 2001-JP1442		20010226	

	NUMBER	DATE
PRIORITY INFORMATION:	AU 2000-5850	20000228

10/694,467

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 1769
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula (I) wherein X1 ? is bond or --O(CH.sub.2).sub.m-- (in which m is an integral number of 1, 2 or 3); X.sub.2 is bond, --(CH.sub.2).sub.n--, etc. (in which n is an integral number of 1, 2 or 3); R.sub.1 is hydrogen or amino protective group; R.sub.2 is hydroxy(lower)alkyl or (lower)alkoxy(lower)alkyl; A is phenyl, pyridyl, indolyl or carbazolyl, each of which may be substituted with one or two substituent(s) selected from the group consisting of halogen, hydroxy, lower alkyl, etc.; and B is phenyl or pyridyl, each of which may be substituted with one or two substituent(s) selected from the group consisting of halogen, hydroxy, nitro, etc.; and a pharmaceutically acceptable salt thereof which is useful as a medicament. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **204592-94-9P 357409-00-8P**
(preparation of phenoxyaminopropanols as β3 adrenergic receptor agonists for treatment of pollakiuria, urinary incontinence, wasting conditions, or emaciation)

RN 204592-94-9 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 357409-00-8 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

L5 ANSWER 3 OF 6 USPATFULL on STN

ACCESSION NUMBER:	2002:295187 USPATFULL
TITLE:	Selective B3 adrenergic agonists
INVENTOR(S):	Crowell, Thomas A., Indianapolis, IN, UNITED STATES Evrard, Deborah A., Indianapolis, IN, UNITED STATES Jones, Charles D., Indianapolis, IN, UNITED STATES Muehl, Brian S., Indianapolis, IN, UNITED STATES Rito, Christopher J., Mooresville, IN, UNITED STATES Shuker, Anthony J., Indianapolis, IN, UNITED STATES Thorpe, Andrew J., Ann Arbor, MI, UNITED STATES Thrasher, Kenneth J., Indianapolis, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002165234	A1	20021107
	US 6686372	B2	20040203
APPLICATION INFO.:	US 2002-120302	A1	20020410 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-610096, filed on 30 Jun 2000, GRANTED, Pat. No. US 6413991 Division of Ser. No. US 1998-68192, filed on 4 May 1998, GRANTED, Pat. No. US 6140352 A 371 of International Ser. No. WO 1997-US15230, filed on 28 Aug 1997, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-25818P	19960905 (60)
	US 1996-29228P	19961030 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288
NUMBER OF CLAIMS:	52
EXEMPLARY CLAIM:	1
LINE COUNT:	3257

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β.sub.3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention

provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **204592-90-5P 204592-94-9P 204592-97-2P**
204593-31-7P 204593-32-8P 204593-36-2P
204593-37-3P
(preparation of carbazole derivs. as adrenergic agonists)

RN 204592-90-5 USPATFULL

CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]propyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204592-94-9 USPATFULL

CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204592-97-2 USPATFULL

CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 204593-31-7 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-[(1-fluoro-9H-carbazol-4-yl)oxy]-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204593-32-8 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-[(8-fluoro-9H-carbazol-4-yl)oxy]-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204593-36-2 USPATFULL
CN Butanedioic acid, compd. with (S)-6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-3-pyridinecarboxamide (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 204593-37-3 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



L5 ANSWER 4 OF 6 USPATFULL on STN

ACCESSION NUMBER:	2002:160746 USPATFULL
TITLE:	Selective β3 adrenergic agonists
INVENTOR(S):	Crowell, Thomas A., Indianapolis, IN, United States Evrard, Deborah A., Indianapolis, IN, United States Jones, Charles D., Indianapolis, IN, United States Muehl, Brian S., Indianapolis, IN, United States Rito, Christopher J., Mooresville, IN, United States Shuker, Anthony J., Indianapolis, IN, United States Thorpe, Andrew J., Ann Arbor, MI, United States Thrasher, Kenneth J., Indianapolis, IN, United States
PATENT ASSIGNEE(S):	Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6413991	B1	20020702
APPLICATION INFO.:	US 2000-610096		20000630 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 68192, now patented, Pat. No. US 6140352		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-25818P	19960905 (60)
	US 1996-29228P	19961030 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Morris, Patricia L.
LEGAL REPRESENTATIVE: Voy, Gilbert T., Skelton, Jeffrey J.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3013
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: ##STR1##

The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **204592-90-5P 204592-94-9P 204592-97-2P**
204593-31-7P 204593-32-8P 204593-36-2P
204593-37-3P
(preparation of carbazole derivs. as adrenergic agonists)

RN 204592-90-5 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]propyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204592-94-9 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204592-97-2 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 204593-31-7 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-[(1-fluoro-9H-carbazol-4-yl)oxy]-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204593-32-8 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-[(8-fluoro-9H-carbazol-4-yl)oxy]-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204593-36-2 USPATFULL
CN Butanedioic acid, compd. with (S)-6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-3-pyridinecarboxamide (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 110-15-6
CMF C4 H6 O4

$HO_2C-CH_2-CH_2-CO_2H$

RN 204593-37-3 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



L5 ANSWER 5 OF 6 USPATFULL on STN

ACCESSION NUMBER:	2000:146398 USPATFULL		
TITLE:	Carbazolyl-substituted ethanolamines as selective β-.sub.3 agonists		
INVENTOR(S):	Crowell, Thomas A., Indianapolis, IN, United States Evrard, Deborah A., Indianapolis, IN, United States Jones, Charles D., Indianapolis, IN, United States Muehl, Brian S., Indianapolis, IN, United States Rito, Christopher J., Mooresville, IN, United States Shuker, Anthony J., Indianapolis, IN, United States Thorpe, Andrew J., Ann Arbor, MI, United States Thrasher, Kenneth J., Indianapolis, IN, United States		
PATENT ASSIGNEE(S):	Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6140352		20001031
	WO 9809625		19980312
APPLICATION INFO.:	US 1998-68192		19980504 (9)
	WO 1997-US15230		19970828
			19980504 PCT 371 date
			19980504 PCT 102(e) date
	NUMBER		DATE
PRIORITY INFORMATION:	US 1996-25818P		19960905 (60)
	US 1996-29228P		19961030 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Stockton, Laura L.		
LEGAL REPRESENTATIVE:	Voy, Gilbert T.		
NUMBER OF CLAIMS:	41		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3226		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: ##STR1## The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **204592-90-5P 204592-94-9P 204592-97-2P 204593-31-7P 204593-32-8P 204593-36-2P 204593-37-3P**
(preparation of carbazole derivs. as adrenergic agonists)

RN 204592-90-5 USPATFULL

CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]propyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204592-94-9 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204592-97-2 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 204593-31-7 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-[(1-fluoro-9H-carbazol-4-yl)oxy]-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204593-32-8 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-[(8-fluoro-9H-carbazol-4-yl)oxy]-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204593-36-2 USPATFULL
CN Butanedioic acid, compd. with (S)-6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-3-pyridinecarboxamide (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 110-15-6
CMF C4 H6 O4



RN 204593-37-3 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



L5 ANSWER 6 OF 6 USPAT2 on STN

ACCESSION NUMBER:	2002:295187 USPAT2
TITLE:	Selective β3 adrenergic agonists
INVENTOR(S):	Crowell, Thomas A., Indianapolis, IN, United States Evrard, Deborah A., Indianapolis, IN, United States Jones, Charles D., Indianapolis, IN, United States Muehl, Brian S., Indianapolis, IN, United States Rito, Christopher J., Mooresville, IN, United States Shuker, Anthony J., Indianapolis, IN, United States Thorpe, Andrew J., Ann Arbor, MI, United States Thrasher, Kenneth J., Indianapolis, IN, United States
PATENT ASSIGNEE(S):	Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6686372	B2	20040203
APPLICATION INFO.:	US 2002-120302		20020410 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-610096, filed on 30 Jun 2000 Division of Ser. No. US 68192, now patented, Pat. No. US 6140352		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-25818P	19960905 (60)

US 1996-29228P 19961030 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Morris, Patricia L.
LEGAL REPRESENTATIVE: Voy, Gilbert T., Skelton, Jeffrey J.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2937
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β.sub.3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **204592-90-5P 204592-94-9P 204592-97-2P**
204593-31-7P 204593-32-8P 204593-36-2P
204593-37-3P
(preparation of carbazole derivs. as adrenergic agonists)
RN 204592-90-5 USPAT2
CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]propyl]phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204592-94-9 USPAT2
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204592-97-2 USPAT2
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 204593-31-7 USPAT2
CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-[(1-fluoro-9H-carbazol-4-yl)oxy]-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204593-32-8 USPAT2
CN 3-Pyridinecarboxamide, 6-[4-[2-[[3-[(8-fluoro-9H-carbazol-4-yl)oxy]-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 204593-36-2 USPAT2
CN Butanedioic acid, compd. with (S)-6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-3-pyridinecarboxamide (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 110-15-6
CMF C4 H6 O4

$HO_2C-CH_2-CH_2-CO_2H$

RN 204593-37-3 USPAT2
CN 3-Pyridinecarboxamide, 6-[4-[2-[[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 204592-94-9
CMF C31 H32 N4 O4

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



=>